Shenzhen Eye Hospital, Jinan University, Shenzhen Eye Institute, 18th Zetian Road, Futian District, Shenzhen, 518040, China.
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC, 3002, Australia.
Int Ophthalmol. 2024 Jun 23;44(1):259. doi: 10.1007/s10792-024-03168-9.
In this study we investigated the efficacy of short-term intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) in treating traumatic submacular hemorrhage.
A total of 115 patients were diagnosed with submacular hemorrhage between 2018 and 2022 at Shenzhen Eye Hospital. In a retrospective analysis, we examined 13 of these patients who presented with submacular hemorrhage and choroidal rupture due to ocular trauma. Eight patients were treated with intravitreal anti-VEGF injection and 5 with oral drugs. We systematically analyzed changes in their ocular conditions pre and post-treatment. The evaluations encompassed best-corrected visual acuity (BCVA), optical coherence tomography, fundus fluorescein angiography, and retinal imaging.
The 13 patients diagnosed with submacular hemorrhage comprised of 10 males and 3 female, with their age ranging between 27 and 64 years, with an average age of 38.1 years (standard deviation [SD]: 11.27). A statistically significant reduction in central foveal thickness (CFT) was observed following intravitreal injections of anti-VEGF drugs (P = 0.03). In control group, the CFT was reduced without statistical significance (P = 0.10). The BCVA of the patients in treatment group improved significantly from 1.15 (SD: 0.62. Range: 0.4-2) to 0.63 (SD: 0.59. Range: 0.1-1.6), indicating an average increase of 4.13 lines (SD: 3.36. Range: 0-9) as measured by the visual acuity test using an eye chart (P = 0.01). The difference between baseline visual acuity and final visual acuity was not statistically significant in control group (P = 0.51).
Short-term administration of anti-VEGF drugs exhibited significant efficacy in reducing submacular hemorrhage following ocular trauma and enhancing visual acuity.
本研究旨在探讨短期玻璃体内注射抗血管内皮生长因子（anti-VEGF）治疗外伤性黄斑下出血的疗效。
回顾性分析 2018 年至 2022 年在我院就诊的 115 例黄斑下出血患者，其中 13 例因眼外伤导致黄斑下出血合并脉络膜破裂。8 例患者接受玻璃体腔注射抗 VEGF 治疗，5 例患者接受口服药物治疗。系统分析患者治疗前后眼部情况的变化。评估包括最佳矫正视力（BCVA）、光学相干断层扫描（OCT）、眼底荧光素血管造影和视网膜成像。
13 例黄斑下出血患者中，男 10 例，女 3 例；年龄 2764 岁，平均年龄 38.1 岁（标准差 11.27）。玻璃体内注射抗 VEGF 药物后，中央黄斑厚度（CFT）明显降低（P=0.03）。对照组 CFT 虽有降低，但无统计学意义（P=0.10）。治疗组患者的 BCVA 从 1.15（标准差：0.62. 范围：0.42）显著提高至 0.63（标准差：0.59. 范围：0.11.6），视力表检查平均提高 4.13 行（标准差：3.36. 范围：09），差异有统计学意义（P=0.01）。对照组患者的基线视力和最终视力差异无统计学意义（P=0.51）。
短期应用抗 VEGF 药物治疗眼外伤后黄斑下出血，可显著减轻黄斑下出血，并提高视力。
